Scharf Investments LLC Sells 268,928 Shares of Smith & Nephew plc (NYSE:SNN)

Scharf Investments LLC decreased its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 9.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,631,524 shares of the medical equipment provider’s stock after selling 268,928 shares during the quarter. Smith & Nephew makes up about 1.9% of Scharf Investments LLC’s holdings, making the stock its 22nd biggest position. Scharf Investments LLC owned approximately 0.60% of Smith & Nephew worth $64,683,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Dimensional Fund Advisors LP lifted its position in shares of Smith & Nephew by 58.2% in the second quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock worth $12,995,000 after buying an additional 193,046 shares during the last quarter. Marshall Wace LLP grew its stake in Smith & Nephew by 257.1% in the 2nd quarter. Marshall Wace LLP now owns 102,722 shares of the medical equipment provider’s stock valued at $2,545,000 after buying an additional 73,960 shares during the last quarter. Creative Planning raised its holdings in Smith & Nephew by 27.0% in the 2nd quarter. Creative Planning now owns 48,474 shares of the medical equipment provider’s stock worth $1,201,000 after acquiring an additional 10,307 shares during the period. Sanctuary Advisors LLC acquired a new position in Smith & Nephew during the 2nd quarter worth $627,000. Finally, GAMMA Investing LLC boosted its holdings in Smith & Nephew by 160.0% during the third quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 1,389 shares during the period. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Stock Performance

NYSE SNN opened at $25.38 on Friday. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The firm has a 50-day simple moving average of $25.04 and a 200 day simple moving average of $27.66. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SNN shares. Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Berenberg Bank downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, StockNews.com cut Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.